Question

Difficulty: MediumHematology and Oncology

Following treatment for a newly diagnosed deep venous thrombosis, a 4545-year-old woman develops severe, worsening pain over her abdomen and left thigh. She sought care at an urgent care clinic 33 days prior for left leg swelling and was immediately prescribed oral warfarin monotherapy. Her past medical history is significant for obesity and type 22 diabetes mellitus. Current medications include metformin and warfarin. Her temperature is 37.1∘C37.1^\circ\text{C} (98.8∘F98.8^\circ\text{F}), blood pressure is 134/82 mmHg134/82\text{ mmHg}, and pulse is 88/min88/\text{min}. Physical examination reveals well-demarcated, exquisitely tender, purpuric lesions with central black eschars over her abdomen and thighs. The remainder of the examination is unremarkable. Laboratory studies show:

Hemoglobin: 13.2 g/dL13.2\text{ g/dL}
Platelets: 210,000/mm3210,000/\text{mm}^3
Leukocytes: 7,500/mm37,500/\text{mm}^3
Prothrombin time: 24 seconds24\text{ seconds} (INR: 2.22.2)
Activated partial thromboplastin time: 32 seconds32\text{ seconds}

Which of the following is the most likely underlying mechanism for this patient's current skin findings?

  1. A
    Autoantibody-mediated platelet activation and clearance
  2. B
    Inhibition of hepatic cytochrome P450 enzymes causing spontaneous hemorrhage
  3. Rapid decline of a vitamin K-dependent endogenous anticoagulantAnswer
  4. D
    Synergistic bacterial invasion of the subcutaneous tissue and fascia
  5. E
    Delayed type IV cell-mediated hypersensitivity reaction to oral medication

Answer

The mechanism for this patient's skin findings is the rapid decline of a vitamin K-dependent endogenous anticoagulant (Protein C), leading to a transient hypercoagulable state.
The correct answer accurately describes the pathophysiology of warfarin-induced skin necrosis. Warfarin acts by inhibiting the hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X) as well as the endogenous anticoagulant proteins C and S. Because Protein C has a significantly shorter half-life (approximately 88 hours) compared to the procoagulant factors (e.g., Factor II has a half-life of 6060 hours), its rapid depletion during the first few days of warfarin therapy creates a paradoxical, transient hypercoagulable state. This leads to microvascular thrombosis within the dermal and subcutaneous vessels, clinically manifesting as exquisitely painful purpura that rapidly progress to dark, necrotic eschars. This complication is classically seen when warfarin is initiated without a "bridge" of a fast-acting anticoagulant (like heparin) or in patients with an underlying hereditary Protein C deficiency.

Step-by-Step Solution

1
Analyze the patient's presentation and recent medication history.
The patient developed painful, necrotic skin lesions (eschars) on her abdomen and thighs exactly 33 days after initiating warfarin monotherapy.
Establishing the precise timeline between medication initiation and symptom onset isolates the etiology to a drug-induced complication.
2
Evaluate the laboratory findings to rule out alternative diagnoses.
Platelet count, hemoglobin, and leukocytes are entirely normal. The INR is therapeutic at 2.22.2.
Normal platelets rule out heparin-induced thrombocytopenia (HIT), and the therapeutic INR combined with a lack of fever rules out supratherapeutic hemorrhage and infectious etiologies.
3
Connect the pathophysiology of warfarin to the specific clinical findings.
Warfarin inhibits both procoagulant factors and anticoagulant proteins. Protein C has the shortest half-life (88 hours) and depletes first, causing transient hypercoagulability.
This early hypercoagulable state leads to microvascular thrombosis in the dermal vessels, resulting in the classic presentation of warfarin-induced skin necrosis.

Key Concept

Warfarin-induced skin necrosis occurs due to a transient hypercoagulable state caused by the rapid depletion of Protein C, which has a shorter half-life than the vitamin K-dependent procoagulant factors.
Rate this question